Sex differences in response to bDMARDs in RA, PsA & SpA? YES. Data from BIOREG- 477 RA, 150 PsA, 312 SpA treated with rap TNFi. Men respond better to TNFi in all groups POS0208 #EULAR2021 @RheumNow @eular_org https://t.co/7FoI3p0qwe

2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU

wonder if vit D is a surrogate for poor health, low SES, diet? In #SARSCoV2 infection low vit D has worse outcomes but clusters racially (⬇️ by skin tone) & seems related to SES. But perhaps adding vit D can help immune system & be anti-inflammatory #EULAR2021 @RheumNow POS0100 https://t.co/TEf52bLs0i

• https://twitter.com/appletonlab/status/1400867603019665419

Deucravacitinib (TYK2i) - phase II trial for PsA ⭐️ACR20, 50, 70 response ⭐️HAQ-DI response ⭐️LEI/SPARCC response ⭐️MDA response Abs#OP0227 #EULAR2021 @RheumNow

Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic ⭐️ACR20, 50,70 response ⭐️significant resolution of enthesitis/dactylitis Abs#OP0228 #EULAR2021 @RheumNow

Latest GRAPPA guidelines for treatment of PsA Abs#OP0229 #EULAR2021 @RheumNow https://t.co/YlHHQsFGC8

What can define +MRI for active spine lesions in axSpA? *⃣ BME in >/=4 vertebral corners (VCs) *⃣BME in >/= 3 VCs if w/ at least 1 non-corner inflamm lesion *⃣BME in >/=1 VC if w/ at least 2 VC fat lesions Such cut-offs achieve >/= 95% specificity OP0252. #EULAR2021 @Rheumnow https://t.co/5CTan2BgLK

Lower ILD incidence in PsA than RA in a large Nordic registry ⭐️ No significant ⬆️ in ILD in those using MTX Abs#OP0222 #EULAR2021 @RheumNow https://t.co/lgGhu1Hmd6

Key points on phenotypes in PsA per Dr. Dafna Gladman: ⭐️Oligoarticular & polyarticular PsA pts have the same burden of dz ⭐️Dactylitis assoc w/ greater dz severity & US synovitis + erosive changes in DMARD-naive early PsA pts #EULAR2021 @RheumNow

Dr Dehlin presents Swedish data showing ⬆️ risk of all cause mortality (HR: 1.08 (95% CL: 1.05-1.11) and most comorbidities but a ⬇️ risk dementia in gout 0.68 (0.60-0.77) @RheumNow #EULAR2021 Abstr#OP0208 https://t.co/0ojpSbfIHM

#EULAR2021 Gender differences in chronic #arthritis 🙋🙋‍♂️ ▶️ POS1061: The Italian prospective SIRENA study: women do worse at the onset of #psoriaticarthritis 🇮🇹 ▶️ POS0208: The Austrian Registry BIOREG: women showed lower response rates to #TNFi 🇦🇹 > LA https://t.co/JNxrqimp2Y

Phenotypes in axPsA per Dr. Gladman: ⭐️15% develop axial dz at 10y: # of radiographic damaged joints, periostitis, & ⬆️ESR predictive. HLA-B27 no longer predictive ⭐️Buttock pain & IBD more common in axial dz ⭐️M had more axial dz + radiographic damage #EULAR2021. @Rheumnow

Dr Deodhar on upadacitinib in axial PsA. Appears to be effective in combined analysis of SELECT-PsA 1 and 2. @RheumNow #EULAR2021 Abstr#0233 https://t.co/fBMWVb3oBd